RETA-10MG

Retatrutide 10mg

Metabolic Research

Retatrutide - a novel GIP/GLP-1/glucagon triple receptor agonist. Among the most advanced incretin-axis research compounds, studied for simultaneous multi-receptor modulation of energy homeostasis, adiposity, and glucose metabolism.

89,99 €

≥99% HPLC purity

Third-party tested · Discreet packaging · Ships from the EU

Specifications
CAS
2381089-83-2
MW
4731.3 g/mol
SKU
RETA-10MG
Storage
−20 °C, dry, protected from light
Usage Notes

This compound is intended exclusively for in vitro research. Refer to peer-reviewed literature for dosing protocols and experimental methodologies.

Disclaimer: Not for human or animal consumption. Not approved by EMA or FDA.

For in vitro research use only. Not for human or animal consumption.

Retatrutide 10mg

Research profile

Overview

Retatrutide (LY3437943) is a synthetic peptide engineered to simultaneously agonise three key metabolic receptors: glucose-dependent insulinotropic polypeptide receptor (GIPR), glucagon-like peptide-1 receptor (GLP-1R), and glucagon receptor (GCGR). This triple receptor engagement represents one of the most advanced incretin research pharmacology profiles currently studied.

Key Research Areas

  1. Triple Incretin Receptor Agonism

    Simultaneous engagement of GIP-R, GLP-1R, and GCGR modulates complementary and synergistic pathways in energy homeostasis – a more comprehensive metabolic signalling profile than single or dual agonists.

  2. Adipose Tissue Research

    Phase 2 clinical data published in the NEJM (2023) demonstrated substantial body weight reduction, making it a central compound in obesity mechanism research.

  3. Glucose Homeostasis

    GLP-1 and GIP components contribute to glucose-dependent insulin secretion; the glucagon component adds hepatic glucose output modulation.

  4. Hepatic Research

    GCGR agonism studied for its role in NAFLD/NASH models through hepatic lipid oxidation and gluconeogenesis modulation.

  5. Thermogenesis Models

    Glucagon component investigated for brown adipose tissue activation and increased basal metabolic rate.

Specifications

CAS 2381089-83-2
Molecular Weight 4731.3 g/mol
Purity ≥99% (HPLC verified)
Form Lyophilised powder, 10 mg per vial (3ml)

For in vitro laboratory research use only. Not for human or animal administration.

Reviews

There are no reviews yet.

Be the first to review “Retatrutide 10mg”

Your email address will not be published. Required fields are marked *